Health Ministry’s plan to purchase new Covid-19 therapy tablet gets the green light

Yesterday, the CCSA approved a proposal from the Public Health Ministry to procure a brand new oral therapy for Covid-19. The ministry plans to purchase 50,000 courses of the anti-viral Molnupiravir drug developed by pharmaceutical agency Merck. The proposal now goes to Cabinet for ultimate approval. The news was confirmed by CCSA spokesman, Dr Taweesin Visanuyothin, who would not be drawn on price or delivery occasions.
According to a Thai PBS World report, Merck has been accused of overcharging for the drug, with a 5-day course of therapy priced at US$712. Analysts at Harvard and King’s College London say the manufacturing value is round US$1.seventy four per capsule, equating to US$17.seventy four for a full course of remedy. The US authorities has already handed over US$712 per course, which a senior economist on the Centre for Economic and Policy Research notes is a 4,000% mark-up.
In related Complete , Taweesin says the Public Health Ministry plans to acquire another 127 million Covid vaccine doses this yr, which incorporates sixty two.5 doses of the Chinese Sinopharm vaccine and the long-awaited Moderna vaccine. The CCSA spokesman says officials expect to achieve a milestone of a minimum of half the inhabitants vaccinated this month, or 70% for those residing in Covid-free parts of the nation.
For extra information on Covid-19 Insurance, CLICK HERE..

Leave a Comment